AIM ImmunoTech Inc. (Form: 8-K, Received: 06/17/2022 09:01:29)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 13, 2022

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

Delaware	001-27072	52-0845822
(state or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

2117 SW Highway 484, Ocala FL		34473
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (352) 448-7797

AIM ImmunoTech Inc.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AIM		NYSE American

Item 1.01 Entry into a Material Definitive Agreement.

On June 13, 2022, we executed a work order with Amarex Clinical Research LLC (“Amarex”) our contract research organization, pursuant to which Amarex will manage the clinical trial entitled: “A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients with Post-COVID Conditions,” once FDA authorization to proceed is received. The study will be conducted at up to 10 sites in the United States. We are sponsoring the study. Per the work order, we anticipate that the study will cost approximately $4.4 million which includes pass through costs of approximately $125,470, investigator costs estimated at about $2.4 million and excludes certain other third-party costs and escalations. A copy of the Amarex work order is filed herewith as Exhibit 10.1.

Cautionary Statement

This Current Report on Form 8-K and the exhibit filed herewith, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the PSLRA. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. We are in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and the presentation sets forth our current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether the Study concerning the efficacy and safety of Ampligen® in patients with Post-COVID Conditions or other current or planned clinical trials will be successful, yield favorable data or not require additional funding, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Even if Ampligen® proves effective in treating Post-COVID Conditions, no assurance can be given that our actions toward proving this will be given first priority or that another treatment that eventually proves capable will not make our efforts ultimately unproductive, major pharma companies may be working to develop their own disease treatments. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the presentation. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. In addition, many countries, including Argentina, are dealing with COVID-19 outbreaks and have made that their primary focus. We believe that this may be delaying our commercialization of Ampligen® in Argentina until COVID-19 is more under control. We cannot assure that our potential foreign operations will not be adversely affected by these risks.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

10.1		June 13, 2022 Amarex Work Order (portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AIM IMMUNOTECH INC.

June 17, 2022	By:	/s/ Thomas K. Equels
		Thomas K. Equels, CEO

Exhibit 10.1

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Response to AIM ImmunoTech’s

Request for Proposal for Trial Services to

Support a Phase II Study of Ampligen in Patients

with Post-COVID Conditions

June 13, 2022

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Important Information

This proposal for a Project Work Order is provided to AIM ImmunoTech Inc (AIM) for the purpose of its evaluation and the information contained herein is not intended to be used by (AIM) for any other purpose than the subject of this proposal. (AIM) agrees not to voluntarily disclose any of the information contained herein to any third party without the prior written consent of Amarex Clinical Research, LLC (Amarex).

This proposal document is subject to negotiation and, when the final version is signed by both parties, shall create a Project Work Order with legal obligations on the part of both parties.

Proposal Expiration Date: August 13, 2022

Prepared for:

AIM ImmunoTech Inc

783 Jersey Avenue

New Brunswick, NJ 08901

Phone: 352-260-7797

Fax: 724-260-6742

Prepared by:

Amarex Clinical Research, LLC

20201 Century Boulevard, Suite 450

Germantown, MD 20874

Phone: (301) 528-7000

Fax: (301) 528-2300

Amarex’s Response to AIM’s Request for Proposal	6/13/2022
Amarex Clinical Research, LLC Confidential and Proprietary Information	Page i

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Our Understanding of AIM’s Needs

Based on our discussions with AIM, Amarex understands that AIM plans to conduct a trial entitled: “A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen^® in Patients with Post-COVID Conditions.” The study will be conducted at up to 10 sites in the United States. No interim analysis is planned.

Study Parameters

Following is a list of study parameters Amarex has used in order to prepare this proposal response:

Table 3. Study Parameters Used to Prepare This Proposal

STUDY PARAMETERS
Number of sites	10
Number of countries participating in study	1
Number of subjects screened	170
Number of subjects randomized/enrolled	80
Number of subjects completed	80
SITE MONITORING AND AUDITING
Number of qualification sites	20
Number of site initiation visits	10
Number of interim monitoring sites	40
Number of closeout visits	10
IRB MANAGEMENT
Number of Local IRB to manage	10
Number of Central IRB to manage	1
Number of DSMB meetings to review data	1
Number of statistical tables per DSMB	10/10
Number of statistical listings per DSMB	10/10
MEDICAL MONITORING
Estimated number of SAEs	5
Estimated number of reportable events	1
DATA MANAGEMENT
Estimated Number of Adverse Events, Concomitant Medications, and Medical Histories to code	2,210
Number of unique pages in eCRF book	20
Number of central labs & vendors	2
BIOSTATISTICS
Number of stat. tables for final analysis (uniques/replicates)	30/20
Number of listings for final analysis (uniques/replicates)	30/20
Number of graphs for final analysis (unique/replicate)	5/0
CLINICAL STUDY REPORT WRITING
Write final clinical trial report	Yes
PROJECT MANAGEMENT
Number of months for project setup	2
Number of months for enrollment	4
Number of months for follow-up (treatment period)	3
Number of months of active study phase for monitoring	7
Number of months for close out	2
Number of months of project management (including set up and close out)	11

Amarex’s Response to AIM’s Request for Proposal	6/13/2022
Amarex Clinical Research, LLC Confidential and Proprietary Information	Page 1

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Proposed Amarex Direct Services Budget

(US Dollars)

AMAREX DIRECT SERVICES FEES
Bid ID	Service	Unit Description	Unit Cost $	No. Units	Total Cost $	Category Total $
B	PROJECT MANAGEMENT
	Meetings, Training, and Study Start Up
11	Prepare for and Attend Kick-off Meeting & Study Start-Up	per protocol	$ [***]	1	$ [***]
16	Prepare for and Attend Project Team Training	per day	$ [***]	1	$ [***]
	Communication and Tracking
17	Coordinate Amarex's Internal Project Team	per month	$ [***]	11	$ [***]
18	Communicate with Sponsor (includes standard teleconferences with activities reports and emails)	per month	$ [***]	11	$ [***]
19	Manage Central Labs/Vendors	per lab-vendor/per month	$ [***]	14	$ [***]
20	Tracking Systems Setup	fixed fee	$ [***]	1	$ [***]
27.1	Management of Payments to Sites, IRBs, Labs, and/or Vendors	per payment / site, IRB or vendor	$ [***]	61	$ [***]	$ [***]
D	PRODUCT MANAGEMENT
59	Set up of WebView IRT product supply tracking and email alert system. Track drug shipments to sites, supply depots, auto-email requests for resupply based on randomization. Require acknowledgement email from supply depot.	per project	$ [***]	1	$ [***]
60	Maintenance for WebView IRT Product Resupply and Tracking	per site per month	$ [***]	20	$ [***]
63	Support Initial Drug / Device Shipments	per site per shipment	$ [***]	10	$ [***]	$ [***]
E	DATA MANAGEMENT SERVICES
	Data Management
65	Develop Data Management Plan	per project	$ [***]	1	$ [***]
73	Standard Data Cleaning (Run edit checks; generate, process, and track data queries)	per query	$ [***]	800	$ [***]
78	Develop Edit Specifications	per project	$ [***]	1	$ [***]
79	Conduct QC Audit of Interim Clinical Database (5% of pts (min 5 max 50) for all data per lock)	per subject	$ [***]	2	$ [***]
	Data Operations
86	Program Edit Checks	per edit check	$ [***]	200	$ [***]
88	Set Up Data Transfer from Vendors	fixed cost/per vendor	$ [***]	2	$ [***]
89	Receive and Reconcile Headers of Clean Data from Vendors	per transfer/per vendor	$ [***]	14	$ [***]
91	Set Up Transfer of Final SAS Data to Sponsor (in Amarex's format)	per dataset	$ [***]	40	$ [***]
92	Perform Data Transfer to Sponsor (Including export of final SAS Analysis Datasets)	per transfer	$ [***]	1	$ [***]
	EDC Support
96	Prepare EDC Manual and Completion Instructions (includes up to 1 round of edits)	per manual	$ [***]	1	$ [***]
97	Prepare User Acceptance Testing (UAT) Management Plan	per document	$ [***]	1	$ [***]
98	Conduct QC of EDC Database	per subject enrolled	$ [***]	80	$ [***]
99	Provide Electronic Data Capture Help Desk	per site/per month	$ [***]	70	$ [***]	$ [***]
	WEBVIEW EDC PROGRAMMING
101	Development of CRF Screen Shots	per unique page	$ [***]	20	$ [***]
102	WebView EDC Programming (Initiation)	per study	$ [***]	1	$ [***]
103	WebView EDC Programming (UAT 1)	per study	$ [***]	1	$ [***]
104	WebView EDC Programming (System Activation)	per study	$ [***]	1	$ [***]
105	WebView EDC Maintenance	per month	$ [***]	9	$ [***]	$ [***]
F	CLINICAL SITE SERVICES
	Site Identification and Contracting
106	Prepare Site Identification Plan	per plan	$ [***]	1	$ [***]
107	Perform Site Identification and Present Sites for Site Qualification Visits	per site recommended	$ [***]	15	$ [***]
108	Develop Site Contracts (includes up to 2 rounds of edits)	per contract	$ [***]	1	$ [***]
109	Negotiate Site Contract CTAs	per site	$ [***]	10	$ [***]
110	Negotiate Site Contract Budgets	per site	$ [***]	10	$ [***]
	IRB and Ethics Committee Management
112	Submit and Obtain Initial Approval of Local IRB	per submission per Local IRB	$ [***]	10	$ [***]
113	Submit and Obtain Initial Approval of Central IRB	per submission per Central IRB	$ [***]	1	$ [***]
116	Review and Approve IRB Informed Consent Comments	per IRB	$ [***]	11	$ [***]
117	Review and Approve Site Informed Consent Prior to IRB Submission	per site	$ [***]	10	$ [***]
	Site Regulatory Document Collection
120	Set Up Trial Master File	per study	$ [***]	1	$ [***]
121	Set Up Investigator/Site Regulatory Files	per site	$ [***]	10	$ [***]
122	Conduct Ongoing Regulatory Document Collection, Review, Tracking, and Maintenance of Trial Master File	per site/per month	$ [***]	70	$ [***]
	Monitoring Services
123	Prepare Study Operations Manual (includes up to 2 rounds of edits)	per project	$ [***]	1	$ [***]
124	Prepare Monitoring Guidelines (includes up to 2 round of edits)	per project	$ [***]	1	$ [***]
125	Perform Site Management	per site/per month	$ [***]	90	$ [***]
127	Prepare Documents for Site Initiation	per project	$ [***]	1	$ [***]
128	Conduct Site Qualification Visits (includes prep and visit report in Amarex format)	per one-day visit	$ [***]	20	$ [***]
129	Conduct Study Initiation Visits (includes prep and visit report in Amarex format)	per one-day visit	$ [***]	10	$ [***]
130	Conduct Interim Monitoring Visits (includes prep and visit report in Amarex format)	per one-day visit	$ [***]	40	$ [***]
131	Conduct Close Out Visits (includes prep and visit report in Amarex format)	per one-day visit	$ [***]	10	$ [***]
133	Travel Time for Monitoring Visits	per trip	$ [***]	80	$ [***]	$ [***]

Amarex’s Response to AIM’s Request for Proposal	6/13/2022
Amarex Clinical Research, LLC Confidential and Proprietary Information	Page 2

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

AMAREX DIRECT SERVICES FEES
Bid ID	Service	Unit Description	Unit Cost $	No. Units	Total Cost $	Category Total $
G	SAFETY
143	Set Up Tracking System and SAE/UADE Start Up	fixed fee	$ [***]	1	$ [***]
144	Prepare Safety Management Plan (includes up to 1 round of edits)	per plan	$ [***]	1	$ [***]
145	Prepare Medical Monitoring Plan (includes up to 1 round of edits)	per plan	$ [***]	1	$ [***]
146	Set Up WebView EDC Safety Reporting Module	per project	$ [***]	1	$ [***]
148	Collect, Process, Evaluate SAE/UADE or Pregnancy, and Prepare Narrative	per event	$ [***]	5	$ [***]
149	Prepare CIOMS or MedWatch Form	per reportable event	$ [***]	1	$ [***]
150	Prepare SAE/UADE Follow up Reports	per update	$ [***]	TBD	[***]
153	Revise SAE/UADE Narratives for DSMB Meetings	per event/per meeting	$ [***]	7	$ [***]
154	Distribute SAE/UADE "Dear Dr." Letters to Sites	per letter per site	$ [***]	10	$ [***]
155	Submit Safety Reports to Regulatory Authorities	per reportable event per country	$ [***]	1	$ [***]
159	Set Up of Coding System to Code AEs, ConMeds, and Histories	fixed cost	$ [***]	1	$ [***]
160	Prepare Medical Coding Plan (includes up to 2 rounds of edits)	per plan	$ [***]	1	$ [***]
161	Code Adverse Events, Medications, and Histories (Using MedDRA and WHO Drug ATC Level)	per term	$ [***]	2210	$ [***]	$ [***]
H	DATA SAFETY MONITORING BOARD (DSMB)
163	Establish and Manage 3-Member DSMB	fixed cost	$ [***]	1	$ [***]
164	Develop DSMB Charter (includes up to 1 round of edits)	per project	$ [***]	1	$ [***]
165	Organize, Conduct and Participate in DSMB Meetings	per meeting	$ [***]	2	$ [***]
166	Prepare Statistical Analysis Plan for DSMB	per project	$ [***]	1	$ [***]
167	Program and Produce Unique Tables for DSMB	per unique table	$ [***]	10	$ [***]
168	Program and Produce Replicate Tables for DSMB	per replicate table	$ [***]	10	$ [***]
169	Program and Produce Unique Listings for DSMB	per unique listing	$ [***]	10	$ [***]
170	Program and Produce Replicate Listings for DSMB	per replicate listing	$ [***]	10	$ [***]
172	Prepare Statistical Report for DSMB Meeting (open and closed session reports, includes up to 1 round of edits)	per meeting	$ [***]	1	$ [***]	$ [***]
I	RANDOMIZATION AND ENROLLMENT
176	Develop WebView IRT Enrollment/Randomization Module	per project	$ [***]	1	$ [***]
177	Generate WebView IRT Randomization Code and Plan	per project	$ [***]	1	$ [***]
178	Conduct WebView IRT Enrollment/Randomization Maintenance	per month	$ [***]	7	$ [***]	$ [***]
J	BIOSTATISTICS
182	Prepare Statistical Analysis Plan (includes list of TLGs in Amarex standard format, and data set conventions)	per project	$ [***]	1	$ [***]
189	Program Tables for Final Analysis (unique tables)	per unique table	$ [***]	30	$ [***]
190	Program Tables for Final Analysis (replicate tables)	per replicate table	$ [***]	20	$ [***]
191	Program Listings for Final Analysis (unique listings)	per unique listing	$ [***]	30	$ [***]
192	Program Listings for Final Analysis (replicate listings)	per replicate listing	$ [***]	20	$ [***]
193	Program Graphs for Final Analysis (unique graph)	per unique graph	$ [***]	5	$ [***]
195	Conduct QC Audit of Stats	per lock	$ [***]	1	$ [***]
198	Production and Review of Tables, Listings, and Graphs for Final Analysis (per unique display)	per unique display	$ [***]	65	$ [***]
199	Production and Review of Tables, Listings, and Graphs for Final Analysis (per replicate display)	per replicate display	$ [***]	40	$ [***]
	Other
202	Base ADaM CDISC Conversion (mapping and programming)	per conversion	$ [***]	1	$ [***]	$ [***]
K	MEDICAL WRITING
211	Prepare Final Clinical Study Report Shell (ICH Format) - includes up to one round of edits	per report	$ [***]	1	$ [***]
212	Prepare Subject Narratives for CSR	per narrative	$ [***]	8	$ [***]
213	Prepare Final Clinical Study Report (ICH Format) with Appendices - includes up to two rounds of edits	per report	$ [***]	1	$ [***]
214	Conduct QC Audit of Clinical Study Report	per report	$ [***]	1	$ [***]	$ [***]
M	GENERAL & ADMINISTRATIVE EXPENSES
221	G&A Expenses	per month	$ [***]	11	$ [***]	$ [***]

	TOTAL OF ACTIVITY-BASED COSTING				$ []*

Amarex’s Response to AIM’s Request for Proposal	6/13/2022
Amarex Clinical Research, LLC Confidential and Proprietary Information	Page 3

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

The unit costs provided in the budget are discounted according to certain economies of scale. A reduction of tasks or units could result in higher unit costs for remaining tasks or units.

Additional units in excess of those planned above will be billed at the same unit rate as shown above.

Amarex budgets services by ‘tasks’ as opposed to by hours. Each task has a fixed unit price associated with it and an estimated number of units proposed for the project. Please examine the estimated number of units for each task carefully to make sure they agree with your expectation. Amarex reserves the right to increase its rates on an annual basis. This increase will not exceed 5% per year.

Estimated Pass-Through Costs

ESTIMATED PASS THROUGH COSTS
Bid ID	Expense	Unit Description	Unit Cost $	No. Units	Total Cost $	Category Total $
A	TRAVEL AND MEETINGS
	US Monitoring Visit Costs (Travel and Living)
1	Airfare	per flight	$ [***]	80	$ [***]
2	Ground Transportation	per day	$ [***]	120	$ [***]
3	Parking	per trip	$ [***]	80	$ [***]
4	Hotel Accommodations	per night	$ [***]	40	$ [***]
5	Meals	per day	$ [***]	120	$ [***]	$ [***]
B	PRINTING & ASSEMBLY OF STUDY MATERIALS
35	Investigator Study Binders Printing and Assembly	per site	$ [***]	11	$ [***]
36	Miscellaneous Printing/Copying	per site per month	$ [***]	70	$ [***]	$ [***]
C	SHIPPING COSTS (CRFs, Study Binders, etc.)
39	Overnight delivery (UPS/FedEx)	per site per month	$ [***]	70	$ [***]	$ [***]
E	MISCELLANEOUS
48	DSMB Honorarium	per person per meeting	$ [***]	6	$ [***]
51	Ad Hoc Electronic Data Transfers Over 12MB	per transfer	$ [***]	11	$ [***]
52	WebEx	per month	$ [***]	11	$ [***]	$ [***]

	TOTAL OF ESTIMATED PASS THROUGHS				$ [***]

Pass-through expenses, such as: approved travel, document shipping and printing, and other project related out-of-pocket expenses incurred by Amarex in the conduct of the study will be invoiced to AIM at the actual cost. These expenses will be supported by acceptable documentation or actual receipts.

Third Party Costs

Third party costs are not included in this proposal. They can be further discussed with AIM.

Amarex’s Response to AIM’s Request for Proposal	6/13/2022
Amarex Clinical Research, LLC Confidential and Proprietary Information	Page 4

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Payment Schedule and Terms

Payment Schedule for Services

The payment terms and obligations for the services outlined in this proposal are as follows:

Payment Description	Percentage Due	Amount
Execution of Project Work Order	20%	$ [***]
Monthly Unit-Based Billing	Balance Due	$ [***]
TOTAL		$ []*

Payment Schedule for Pass-Through Expenses

Pass-through expenses such as approved travel, document shipping and printing, and other reasonable expenses will be invoiced to AIM at cost. These expenses will be supported by acceptable documentation or actual receipts and will be invoiced on a monthly basis.

Payment Terms

■

Payments are due 30 days after delivery of an invoice.

■

Late payment fee: 1% per month interest on all past due, unpaid balances.

■

Amarex Clinical Research, LLC Tax ID: [***]

■

Please include Invoice numbers on all payments

■

Payments will be sent to Amarex’s partner company NSF International

■

Payments will be wire transferred to the NSF International bank account at:

[***]

Amarex’s Response to AIM’s Request for Proposal	6/13/2022
Amarex Clinical Research, LLC Confidential and Proprietary Information	Page 5

EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Project Work Order Signatures

In Witness Whereof, AIM ImmunoTech Inc. and Amarex Clinical Research, LLC agree to all items and payment terms and conditions presented in this Project Work Order as indicated by the signatures below of their respective duly authorized representatives as of the “Effective Date”, appearing below.

ACKNOWLEDGED, ACCEPTED, AND AGREED TO:

For and on behalf of AIM ImmunoTech Inc.:		For and on behalf of Amarex Clinical Research, LLC:
Print Name:	Thomas K Equels	Print Name:	Kazem Kazempour
Signature:	/s/Thomas K Equels	Signature:	/s/Kazem Kazempour
Title:	Chief Executive Officer	Title:	President and CEO (Member)
Effective Date:	June 14, 2022	Effective Date:	June 13, 2022

Amarex’s Response to AIM’s Request for Proposal	6/13/2022
Amarex Clinical Research, LLC Confidential and Proprietary Information	Page 6